Introduction {#sec0005}
============

Coronavirus Disease 2019 (COVID-19), which was first reported in Wuhan, China during December 2019, is a newly emerged viral infection caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), also known as the 2019 novel coronavirus (2019-nCoV) ([@bib0120]). This disease is characterized by fever, dry cough, fatigue and lymphopenia, which can also lead to gastrointestinal symptoms, organ dysfunction, rapid progression to a severe acute respiratory syndrome and even death ([@bib0025], [@bib0035]). According to a daily report by the World Health Organization (WHO), as of April 4th, 2020, 1,051,635 cases were confirmed globally, involving 207 countries and regions, including 82,875 cases in China, causing 56,985 deaths in total. The coronavirus COVID-19 pandemic is considered a global health crisis of our time and the greatest challenge we have faced since World War Two.

Two other unusual coronavirus outbreaks occurred in the 21st century, including the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV), causing high mortality rates. As the seventh member of the coronavirus family that infects humans, the 2019-nCoV genome sequence is reported to be approximately 82% identical to the human SARS-CoV ([@bib0005]). The 2019-nCoV has the same cell entry receptor as the SARS-CoV, the angiotensin converting enzyme 2 (ACE2), which regulates the cross-species and human-to-human transmissions of the SARS-CoV ([@bib0105], [@bib0085], [@bib0115], [@bib0040]). ACE2 belongs to the ACE family of dipeptidyl carboxy-dipeptidases and plays a critical role in the RAS systems and in some organs ([@bib0080]). It is distributed broadly in the arterial and the venous endothelial cells, the arterial smooth muscle cells and the cholangiocytes, and especially highly expressed in the renal, the cardiovascular, and the gastrointestinal tissues. This indicates that COVID-19 may involve multiple organs, which may also explain the various extrapulmonary symptoms ([@bib0010]).

Although COVID-19 is characterized by fever and respiratory tract manifestations, data from recent studies suggest that concurrent gastrointestinal symptoms are not uncommon ([@bib0065]). Moreover, it has been reported that the SARS-CoV exhibits an intestinal tropism ([@bib0045]). It is possible that the 2019-nCoV had the same tissue tropism as that of the SARS-CoV, as they had the same functional cell receptor ([@bib0105]). Several studies have found the surface expression pattern of the ACE2 protein in enterocytes of the small intestine, mainly on cells in contact with the external environment. ACE2 is mainly expressed in the endothelium and the vascular smooth muscle cells in the colon ([@bib0040], [@bib0090], [@bib0060]). ACE2 expressed on surface cells of the small intestine is a potential primary entrance for the 2019-nCoV to infect the host and cause gastrointestinal symptoms.

This study aimed to determine the expression pattern of ACE2 gene in the small intestine and attempted to determine the potential mechanism of diarrhea and other gastrointestinal manifestations in patients with COVID-19. Meanwhile, the distribution pattern of ACE2 may insinuate a fecal--oral transmission for the COVID-19. A high virus titer in the digestive tract may indicate a high risk of transmission via feces of the patients, which raises new problems in the disposal of feces.

Materials and methods {#sec0010}
=====================

Clinical data {#sec0015}
-------------

We summarized the clinical data of four recent studies involving clinical characteristics of the COVID-19 to extract the incidence of gastrointestinal symptoms in patients infected with the 2019-nCoV ([@bib0035], [@bib0095], [@bib0070], [@bib0110]). Recorded information included the demographic data and the gastrointestinal symptoms during the whole disease process including anorexia, nausea or vomiting, diarrhea, and abdominal pain. All clinical information was directly obtained from the articles cited above.

Public dataset acquisition and processing {#sec0020}
-----------------------------------------

We used RNA and protein expression data of the *ACE2* gene in different human tissues through the Human Protein Atlas portal (<http://www.proteinatlas.org/>) ([@bib0075]). All data are available online. Gene expression matrix and cell type annotation of single cell RNA-seq (scRNA-seq) data from biopsies of the human terminal ileum across 13 children diagnosed with functional gastrointestinal disease (without inflammation) and ranging in age 6--18 years old. Different cell types were identified by mapping the canonical marker genes in the two-dimensional t-distributed stochastic neighbor embedding (tSNE) map. The TOP principle components were used to project the data using tSNE. Cell labels were used for cell-type annotations. The visualisation results were obtained from the scRNA-seq Single Cell Portal (<https://singlecell.broadinstitute.org/single_cell>) and the data was uploaded by [@bib0125].

Results {#sec0025}
=======

We analyzed data from the 4 most recent studies focused on the clinical features of COVID-19 patients ([Table 1](#tbl0005){ref-type="table"} ). In these 4 cohort studies, the number of confirmed patients was 138, 137, 51 and 140, respectively. The data from three relatively large sample studies indicated that approximately 8--12.9% of the COVID-19 patients had diarrhea. Cohort1 showed anorexia in 39.9%, and cohort 4 found nausea in 17.3% and vomiting in 5% of the 2019-nCoV-infected patients. Meanwhile, multiple clinical reports confirmed positive presence of the 2019-nCoV in the stool of patients. The clinical outcomes indicated that the gastrointestinal tract may be an alternative route for the 2019-nCoV infection apart from the respiratory tract.Table 1Summary of the renal function characteristics of COVID-19 patients in 4 cohorts.Table 1CharacteristicsCohort 1Cohort 2Cohort 3Cohort 4Patient number13813751140Age (years), median (range)56 (22--92)57 (20--83)49\*(16--76)57 (25--87)Sex Male75 (54.3%)61 (44.5%)25 (49%)71 (50.7%) Female63 (45.7%)76 (55.5%)26 (51%)69 (49.3%)Digestive symptoms Anorexia55 (39.9%)NA9 (18%)17/139 (12.2%) Nausea or vomiting14 (10.1%)/5 (3.6%)NA3 (6%)24/139 (17.3%) & 7/139 (5.0%) Diarrhea14 (10.1%)11(8.0%)5(10%)18/139 (12.9%) Abdominal pain3 (2.2%)NANA8/139 (5.8%)[^2]

ACE2 is considered a major functional receptor of the 2019-nCoV in humans. We analyzed the published data from the online datasets to explore the expression level of ACE2 gene in human digestive system. The data from the Human Protein Atlas portal indicated that *ACE2* mRNA expression level was highest in the small intestine of all tissues ([Figure 1](#fig0005){ref-type="fig"} ).Figure 1Data of mRNA expression level of ACE2 in different human tissues from online datasets, data from (A) GTEx portal, (B) The Human Protein Atlas dataset, (C) Consensus dataset. pTPM, transcripts per million.Figure 1

The RNA-seq details section shows detailed information about the individual samples used for the transcript profiling and results of the RNA-seq analysis. Information about some individual samples has been listed in [Table 2](#tbl0010){ref-type="table"} from The Human Protein Atlas, including sex, age and estimated fractions of cell types.Table 2The individual samples used for the transcript profiling of ACE2 in the human small intestinal tissues from the Human Protein Atlas portal.Table 2Small intestine samplesCase 1Case 2Case 3Age (years)653968GenderMaleMaleMaleEstimated fractions of cell types^pTPM^ (%) Glandular cells554030 Smooth muscle cells5515 Other cell types405555[^3]

Furthermore, the protein expression level of ACE2 was relatively higher in the small intestine than that in the other tissues ([Figure 2](#fig0010){ref-type="fig"}A and B), and the results of immunohistochemistry (IHC) also indicated that the protein expression level of ACE2 was significantly higher in the small intestine than in the other tissues ([Figure 2](#fig0010){ref-type="fig"}C and D). These results suggest that cells of the small intestine may be potential target-organ of the 2019-nCoV.Figure 2ACE2 protein expression levels in different human tissues from the Human Protein Atlas portal. (A, B) ACE2 protein expression levels in different tissues. (C,D) IHC staining of ACE2 in the small intestinal tissues.Figure 2

To assess the cell type-specific expression of ACE2, we analyzed datasets containing the scRNA-seq data of the non-inflamed terminal ileum tissue from 13 children diagnosed with functional gastrointestinal disease. We divided single cells into sub-clusters based on the canonical markers and cell classification in the original literature ([Figure 3](#fig0015){ref-type="fig"}A), and the results revealed specific ACE2 expression in the small intestinal epithelium cells (absorptive and crypt enterocytes) ([Figure 3](#fig0015){ref-type="fig"}B). In contrast, ACE2 expression was not observed in goblet, paneth, tuft or enteroendocrine cells. This observation partially matched with that of the previous data based on ACE2 protein expression ([@bib0010]), where small intestinal enterocytes were ACE2-positive and other cells in the small intestine were ACE2-negative. Therefore, ACE2 expression in the small intestinal enterocytes may be a potential mechanism of infection and direct an intestinal epithelial injury by the 2019-nCoV-binding ACE2 as the host cell receptors.Figure 3Single cell analysis of human small intestinal cells using a single cell portal. (A) Small intestinal cell atlas visualised by tSNE. (B) The violin plot showing ACE2 gene expression of major intestinal epithelium cell types.Figure 3

Discussion {#sec0030}
==========

Since COVID-19 emerging in Asia late last year, the virus has spread to every continent except Antarctica. Cases are rising daily in Africa, the Americas, and Europe. COVID-19 has mainly gained attention for its rapid contagious ability and severe respiratory manifestations. The symptoms of COVID-19 are complex and diverse, ranging from an asymptomatic infection to ARDS with multiple organ dysfunction, making it difficult to recognize at a very early stage. In addition to the respiratory system, COVID-19 showed varying degrees of involvement in the digestive system, evidenced by diarrhea, nausea and/or vomiting, anorexia, and abdominal pain, the mechanisms and implications of which have not been determined. It is reported that diarrhea may be underestimated in COVID-19 patients ([@bib0050]). Xiao et al. found that more than half of their hospitalized patients were tested SARS-CoV-2 RNA positive in their stool samples, while no more than 20.0% of confirmed patients were reported with digestive symptoms in other cohorts ([@bib0100]). The research found positive staining of ACE2 and 2019-nCoV in gastrointestinal epithelium from patients with positive 2019-nCoV RNA in their stool, which added convincing evidence that the 2019-nCoV can infect digestive system. 2019-nCoV patient with onset symptom of diarrhea was also reported recently, reminding us of the importance of digestive symptoms in 2019-nCoV infection ([@bib0065]). In our study, we focused on the digestive manifestation and possible mechanism, aiming to offer adjuvant therapeutic methods for patients infected with the 2019-nCoV and exhibiting gastrointestinal symptoms.

ACE2 has been suggested to be the functional receptor for the 2019-nCoV, similar to that for the SARS-CoV. Although ACE2 mRNA is known to be present in virtually all organs, its protein expression is largely unknown. Here, we evaluated the expression pattern of ACE2 in the small intestine of healthy human and mice using online datasets and bioinformatics methods. The results revealed that the expressions of mRNA and protein of the ACE2 gene are extremely high in the intestinal cells especially in enterocytes. Xiao et al. had observed plasma cells and lymphocytes infiltration in 2019-nCoV patients' lamina propria of stomach, duodenum and rectum, accompanied with interstitial edema, instead of direct damage of mucous epithelium ([@bib0100]). Therefore, the 2019-nCoV spike protein may enter the small intestinal enterocytes by binding to ACE2, which induces immune cells infiltration and abnormal intestinal function.

Notably, the results of the study by Hamming et al. indicate that ACE2 is present in all parts of the small intestinal epithelium cells, including the duodenum, the jejunum, and the ileum, but not in enterocytes of the colon ([@bib0010]). Furthermore, the 2019-nCoV may replicate in the enterocytes of the small intestine because the viral RNA can be detected in stool samples of the patients. The high expression of ACE2 protein as a functional receptor for the 2019-nCoV in enterocytes of the small intestine, combined with the presence of the virus in stool samples of the patients, suggests that a fecal--oral transmission may exist. It may also necessitate the collection of stool samples of the suspected patients to help in an early diagnosis and assessment of the disease status. A cluster of cases infected with SARS reported in late March, 2003 in Amoy Garden, a populated residential area in Hong Kong, China should also be noted that the patients were believed to get infected as a result of the unscientific drainage system, which indicated that there were possibilities that virus transmit by a fecal--oral way. We should be wary of the coming warmer seasons, which is also the season when digestive infectious diseases happened with higher incidence, the 2019-nCoV could spread again.

ACE2 is identified as an enzyme that negatively regulates the RAS by converting Ang II and the main bioactive molecule of the RAS. In addition, ACE2 is essential for neutral amino acid transporters in the gut ([@bib0080], [@bib0030]). A study showed that amino acid malnutrition is related to an intestinal inflammation via ACE2, which plays a significant role in amino acid homeostasis, innate immunity, and maintaining intestinal microbiota ([@bib0015]). The ACE2 knockout mice model showed a decline in the uptake of tryptophan, resulting in a decrease in the expression of antimicrobial peptides from small intestinal paneth cells and the change of the intestinal microbiota, leading to a high sensitivity to colitis, which was restored by tryptophan supplementation ([@bib0020]). It explains how the aberrant absorption of tryptophan in the small intestine leads to manifestations of colitis, such as diarrhea ([@bib0015], [@bib0055]). Through this way, ACE2 modulates innate immune responses and influences the composition of the gut microbiota, which may further explain diarrhea observed in the 2019-nCoV patients. As ACE2 being known to be the receptor of the 2019-nCoV, there may be competitive combination of the 2019-nCoV and ACE2, which may inhibit the absorption of dietary tryptophan in the small intestine and end up in the change of the intestinal microbiota and susceptibility to colitis. The absorption function of small intestinal epithelial cells may be interrupted by immune reactions induced by viral infection at the same time. Therefore, intake of foods rich in amino acids, especially tryptophan, may be beneficial for the 2019-nCoV patients. Our study also provides a theoretical basis for the treatment of COVID-19 with microecological preparations.

Conclusion {#sec0035}
==========

Digestive symptoms were common in the 2019-nCoV-infected patients. ACE2 expression on the surface cells of the small intestine may mediate the invasion and amplification of the virus and activation of a gastrointestinal inflammation. It is a possible mechanism of digestive symptoms in the 2019-nCoV infected patients and explains the presence of the virus in stool samples of the patients. The study also necessitates the collection of stool samples of suspected patients to help in an early diagnosis and assessment of the disease status.
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